Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis

Fig. 3

Forest plots of direct and indirect comparison for progression-free survival (PFS) - I. A = Tax, C = Bev + Tax, D = Bev + Cap, G = Bev + Tax+Cap. Bev = bevacizumab, Cap = capecitabine, Tax = taxanes. HR [95%CI] = hazard ratio with 95% confidence interval, NA = not applicable

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us